Ilypsa, Inc., a privately-held biopharmaceutical company pioneering novel non-absorbed drugs for renal and metabolic disorders, today announced the appointment of William D. Waddill as Chief Financial Officer.
Ilypsa, Inc., a privately-held biopharmaceutical company pioneering novel non-absorbed drugs for renal and metabolic disorders, today announced the appointment of William D. Waddill as Chief Financial Officer.